Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01581086 · ClinicalTrials.gov registry record

Vascular Subphenotypes of Lung Disease in HIV & COPD

A clinical trial, sponsored by University of Pittsburgh.

Completed
Registry status
30
Enrollment target

NCT01581086: Completed study, sponsored by University of Pittsburgh.

NCT01581086 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01581086 has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
30 participants
Enrollment target

Study Summary

This study is looking for high blood pressure in the lungs (Pulmonary artery hypertension PAH) in HIV and COPD patients.

Primary Outcome

establish a pulmonary hypertension cohort for translational investigations, to determine the utility of NT-proBNP as a biomarker of PAH

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2012-01
Est. Completion 2017-01
University of Pittsburgh

1,238 total trials

What the finished NCT01581086 record still lists

NCT01581086 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01581086 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01581086 about?

NCT01581086 is a clinical study titled "Vascular Subphenotypes of Lung Disease in HIV & COPD". This study is looking for high blood pressure in the lungs (Pulmonary artery hypertension PAH) in HIV and COPD patients.

What is the current status of trial NCT01581086?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2012-01. Estimated completion is 2017-01.

Who is sponsoring clinical trial NCT01581086?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01581086, the US trial registry maintained by the National Library of Medicine. NCT01581086 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.